Jon Congleton, Mineralys CEO
November 16, 2022 08:30 AM EST
R&D

Months re­moved from a $118M Se­ries B, Min­eralys push­es ahead with PhII hy­per­ten­sion da­ta

Tyler Patchen

News Reporter

In June, the Philadel­phia-based biotech Min­eralys com­plet­ed a $118 mil­lion Se­ries B fi­nanc­ing with back­ing from names like RA Cap­i­tal, push­ing to­ward fin­ish­ing a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times